Keeping risk in context while rethinking the setting of asthma biologics in patient-centered care

Ann Allergy Asthma Immunol. 2020 Aug;125(2):124-125. doi: 10.1016/j.anai.2020.05.029. Epub 2020 Jun 1.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Drug Approval
  • Home Care Services / trends*
  • Humans
  • Omalizumab / therapeutic use*
  • Patient-Centered Care / methods*
  • Precision Medicine
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Asthmatic Agents
  • Omalizumab